Appendix 4E & Annual Report

• Revenues down 5.3% to $788,418
• Loss down 65.4% to $4,787,258
• Initiated Phase 1 trial of RC220 in combination with doxorubicin

Race Oncology Limited has released its Appendix 4E and Annual Report for the 2024-2025 financial year, reporting a 65.4% decrease in loss to $4,787,258 despite a 5.3% decline in revenues to $788,418. The company made significant clinical progress during the year, including the initiation of a Phase 1 clinical trial for its lead drug candidate RC220 in combination with doxorubicin for patients with advanced solid tumors. The trial commenced patient dosing in April 2025, with the first patient safely dosed in June 2025. Race Oncology also strengthened its clinical leadership team with the appointments of Dr. Jose Iglesias as Chief Medical Officer and Dr. Simon Fisher as Vice President of Medical. Additionally, the company announced the successful completion of an FTO-targeted drug discovery program with Monash University's Fragment Platform, identifying 39 unique protein-binding FTO molecules. Race Oncology's financial position remains robust, with $13.67 million in cash and cash equivalents as of June 30, 2025, and the company is well-positioned to continue advancing its clinical programs and delivering value to shareholders.

The company reported a 65.4% decrease in loss for the year to $4,787,258.

Race Oncology remains focused on advancing its RC220 clinical trials, exploring strategic partnerships, and delivering value to shareholders.